search
Back to results

Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment (CRT clinic)

Primary Purpose

Heart Failure

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Imaging guided LV lead positioning
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring Cardiac resynchronization therapy, Echocardiography, Cardiac computed tomography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Symptomatic heart failure (New York Heart Association functional class II - IV) despite stabile optimal medical therapy.
  • Wide QRS ≥ 120 milliseconds on standard ECG.
  • LV systolic dysfunction (EF ≤ 35%).
  • Written informed consent.
  • Accepted for CRT-P or CRT-D treatment

Exclusion Criteria:

  • Life expectancy < 12 months.
  • Recent myocardial infarction (< 3 months).
  • Significant valve disease
  • Chronic atrial fibrillation
  • Pregnancy
  • Severely impaired renal function (estimated glomerular filtration rate (eGFR) < 30 ml/min)
  • Unable to give written informed consent.

Sites / Locations

  • Skane University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Imaging guided LV lead positioning

Standard LV lead positioning

Arm Description

The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.

Outcomes

Primary Outcome Measures

Positive response to CRT treatment
The primary efficacy endpoint will evaluate the effect of echocardiography and cardiac CT guided placement of the left ventricular lead vs standard care (i.e. position of the left ventricular lead at the discretion of the treating physician). Number of patients with positive response to CRT (YES or NO). A positive response is defined as survival in combination with either a reduction in end systolic left ventricular volume ≥ 15% by echocardiography ("volume responder") and / or improvement ≥ 1 NYHA class and ≥10% improvement in 6 minute hall walk test ("clinical responder").

Secondary Outcome Measures

Response to CRT (on-treatment analysis)
Evaluate the effect of optimal LV placement (post hoc analysis of both groups) versus non-optimal LV lead placement. Optimal lead placement is defined as pacing from a viable segment with the latest mechanical activation (by myocardial strain measurement). Outcome measure is the same as in the primary outcome measure.
Heart failure morbidity
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to hospitalisation for worsening of heart failure
Morbidity and mortality
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to a composite endpoint of all cause mortality and hospitalisation for worsening of heart failure (2 years and 5 years).
Mortality
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to all cause mortality
Left ventricular dyssynchrony
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to echocardiography measured changes in LV dyssynchrony
Ventricular tachycardia
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to number of treated ventricular tachycardia episodes
Quality of life
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in the Minnesota Living with heart failure Quality of Life questionnaire
Myocardial viability
Evaluate the concordance in viability assessment using myocardial strain evaluation (echocardiography) compared to cardiac MRI.
Biochemical markers of heart failure
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in blood natriuretic peptide (BNP) levels
Left ventricular systolic function
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in LV ejection fraction
Myocardial viability
Evaluate the concordance between echocardiography (strain evaluation with speckle tracking) and cardiac MRI viability images (late gadolinium enhancement).
MRI left ventricular dyssynchrony
Evaluate if MRI dyssynchroni evaluation has incremental value over echocardiography alone for predicting the effect of cardiac resynchronization therapy.
Left ventricular diastolic dimension
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in left ventricular diastolic dimension

Full Information

First Posted
August 25, 2011
Last Updated
March 27, 2019
Sponsor
Region Skane
Collaborators
Crafoord Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01426321
Brief Title
Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment
Acronym
CRT clinic
Official Title
Individually Tailored Cardiac Resynchronization Therapy - Combing Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in Cardiac Resynchronization Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
August 2011 (Actual)
Primary Completion Date
January 2018 (Actual)
Study Completion Date
December 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane
Collaborators
Crafoord Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
For patients with advanced heart failure, Cardiac Resynchronization Therapy (CRT) has been a major improvement. The treatment improves symptoms and prolongs life in selected patients with heart failure. However, with the current selection criteria and methods for implanting the pacemaker, only 60-70% of the patients derive significant benefit from the treatment. New imaging techniques, including advanced ultrasound and computed tomography, in combination with new versatile multi-pole electrodes, have made an individually tailored therapy possible. Using these techniques in combination, the study will investigate the effect of individually based "optimal" placement of the pacemaker electrodes vs. standard care. The optimal LV electrode position is defined as pacing a viable segment with the latest mechanical delay, targeting a specific segment of the coronary sinus as visualised on cardiac CT. The hypothesis is that this will increase the number of positive responders from 65% to 85%.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
Cardiac resynchronization therapy, Echocardiography, Cardiac computed tomography

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Imaging guided LV lead positioning
Arm Type
Active Comparator
Arm Title
Standard LV lead positioning
Arm Type
No Intervention
Arm Description
The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
Intervention Type
Other
Intervention Name(s)
Imaging guided LV lead positioning
Intervention Description
LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate "optimal" cardiac vein segment is then chosen using the CT images.
Primary Outcome Measure Information:
Title
Positive response to CRT treatment
Description
The primary efficacy endpoint will evaluate the effect of echocardiography and cardiac CT guided placement of the left ventricular lead vs standard care (i.e. position of the left ventricular lead at the discretion of the treating physician). Number of patients with positive response to CRT (YES or NO). A positive response is defined as survival in combination with either a reduction in end systolic left ventricular volume ≥ 15% by echocardiography ("volume responder") and / or improvement ≥ 1 NYHA class and ≥10% improvement in 6 minute hall walk test ("clinical responder").
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Response to CRT (on-treatment analysis)
Description
Evaluate the effect of optimal LV placement (post hoc analysis of both groups) versus non-optimal LV lead placement. Optimal lead placement is defined as pacing from a viable segment with the latest mechanical activation (by myocardial strain measurement). Outcome measure is the same as in the primary outcome measure.
Time Frame
6 months
Title
Heart failure morbidity
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to hospitalisation for worsening of heart failure
Time Frame
6 months 2 years and 5 years
Title
Morbidity and mortality
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to a composite endpoint of all cause mortality and hospitalisation for worsening of heart failure (2 years and 5 years).
Time Frame
6 months 2 years and 5 years
Title
Mortality
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to all cause mortality
Time Frame
6 months, 2 years and 5 years
Title
Left ventricular dyssynchrony
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to echocardiography measured changes in LV dyssynchrony
Time Frame
6 months
Title
Ventricular tachycardia
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to number of treated ventricular tachycardia episodes
Time Frame
6 months 2 years and 5 years
Title
Quality of life
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in the Minnesota Living with heart failure Quality of Life questionnaire
Time Frame
6 months 2 years 5 years
Title
Myocardial viability
Description
Evaluate the concordance in viability assessment using myocardial strain evaluation (echocardiography) compared to cardiac MRI.
Time Frame
Peroperative
Title
Biochemical markers of heart failure
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in blood natriuretic peptide (BNP) levels
Time Frame
6 months
Title
Left ventricular systolic function
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in LV ejection fraction
Time Frame
6 months
Title
Myocardial viability
Description
Evaluate the concordance between echocardiography (strain evaluation with speckle tracking) and cardiac MRI viability images (late gadolinium enhancement).
Time Frame
6 months
Title
MRI left ventricular dyssynchrony
Description
Evaluate if MRI dyssynchroni evaluation has incremental value over echocardiography alone for predicting the effect of cardiac resynchronization therapy.
Time Frame
6 months
Title
Left ventricular diastolic dimension
Description
Evaluate the effect of echocardiography guided LV lead placement compared to standard care in relation to the change in left ventricular diastolic dimension
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Symptomatic heart failure (New York Heart Association functional class II - IV) despite stabile optimal medical therapy. Wide QRS ≥ 120 milliseconds on standard ECG. LV systolic dysfunction (EF ≤ 35%). Written informed consent. Accepted for CRT-P or CRT-D treatment Exclusion Criteria: Life expectancy < 12 months. Recent myocardial infarction (< 3 months). Significant valve disease Chronic atrial fibrillation Pregnancy Severely impaired renal function (estimated glomerular filtration rate (eGFR) < 30 ml/min) Unable to give written informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rasmus Borgquist, MD PhD
Organizational Affiliation
Region Skane
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skane University Hospital
City
Lund
ZIP/Postal Code
221 85
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
33092758
Citation
Borgquist R, Carlsson M, Markstad H, Werther-Evaldsson A, Ostenfeld E, Roijer A, Bakos Z. Cardiac Resynchronization Therapy Guided by Echocardiography, MRI, and CT Imaging: A Randomized Controlled Study. JACC Clin Electrophysiol. 2020 Oct;6(10):1300-1309. doi: 10.1016/j.jacep.2020.05.011. Epub 2020 Aug 12.
Results Reference
derived

Learn more about this trial

Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment

We'll reach out to this number within 24 hrs